Literature DB >> 22500546

Tools to reduce polypharmacy.

Murthy Gokula1, Holly M Holmes.   

Abstract

The reduction in polypharmacy and avoidance of inappropriate medications is a common goal in the care of older persons, regardless of setting. While multidisciplinary teams and regular medication reconciliation and review can identify and reduce medication-related problems, tools to decrease the use of high-risk/low benefit medications can help the individual clinician to improve prescribing. Numerous criteria, tools, algorithms, and scoring systems have been developed for use in a wide range of areas from long-term care to the outpatient setting, and some may not be applicable to individual situations. Not all medication review instruments have been adequately validated, and the tools we have presented have varying levels of evidence to support their use. Clinicians also need to be aware of regulatory, policy, and guideline issues that may impact the use of certain criteria for optimum prescribing. Ultimately, optimizing prescribing by reducing polypharmacy and avoiding inappropriate medications is a highly individualized process for each patient, and clinicians will have to use extensive clinical judgment in using the tools presented here.

Entities:  

Mesh:

Year:  2012        PMID: 22500546     DOI: 10.1016/j.cger.2012.01.011

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN: 0749-0690            Impact factor:   3.076


  12 in total

1.  Inappropriate prescribing in patients accessing specialist palliative day care services.

Authors:  A Todd; H Nazar; H Pearson; L Andrew; L Baker; A Husband
Journal:  Int J Clin Pharm       Date:  2014-06

2.  Potential drug interactions in patients with a history of cancer.

Authors:  L Chen; W Y Cheung
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

3.  Potentially inappropriate medications: predictor for mortality in a cohort of community-dwelling older adults.

Authors:  Mariana Martins Gonzaga do Nascimento; Juliana Vaz de Melo Mambrini; Maria Fernanda Lima-Costa; Josélia Oliveira Araújo Firmo; Sérgio William Viana Peixoto; Antônio Ignácio de Loyola Filho
Journal:  Eur J Clin Pharmacol       Date:  2017-01-20       Impact factor: 2.953

Review 4.  Deprescribing for older patients.

Authors:  Christopher Frank; Erica Weir
Journal:  CMAJ       Date:  2014-09-02       Impact factor: 8.262

Review 5.  Deprescribing in Older Adults With Cardiovascular Disease.

Authors:  Ashok Krishnaswami; Michael A Steinman; Parag Goyal; Andrew R Zullo; Timothy S Anderson; Kim K Birtcher; Sarah J Goodlin; Mathew S Maurer; Karen P Alexander; Michael W Rich; Jennifer Tjia
Journal:  J Am Coll Cardiol       Date:  2019-05-28       Impact factor: 24.094

6.  Attitudes Towards Deprescribing Among Older Adults with Limited Life Expectancy and Their Relatives: A Systematic Review.

Authors:  Alaa Burghle; Carina Lundby; Jesper Ryg; Jens Søndergaard; Anton Pottegård; Dorthe Nielsen; Trine Graabæk
Journal:  Drugs Aging       Date:  2020-07       Impact factor: 3.923

7.  A commercial ARHGEF17/TEM4 antibody cross-reacts with Nuclear Mitotic Apparatus protein 1 (NuMA).

Authors:  Diogjena Katerina Prifti; Annie Lauzier; Sabine Elowe
Journal:  PLoS One       Date:  2022-07-01       Impact factor: 3.752

8.  Combining quality improvement and geriatrics training: the nursing home polypharmacy outcomes project.

Authors:  Gotaro Kojima; Christina L Bell; Bruce Tamura; James Davis; Michiko Inaba; Pia Lorenzo; Patricia Lanoie Blanchette; Wendy Iwasaki; Kamal Masaki
Journal:  Gerontol Geriatr Educ       Date:  2014-06-05

9.  Reducing cost by reducing polypharmacy: the polypharmacy outcomes project.

Authors:  Gotaro Kojima; Christina Bell; Bruce Tamura; Michiko Inaba; Karen Lubimir; Patricia Lanoie Blanchette; Wendy Iwasaki; Kamal Masaki
Journal:  J Am Med Dir Assoc       Date:  2012-09-05       Impact factor: 4.669

10.  Co-prescription trends in a large cohort of subjects predict substantial drug-drug interactions.

Authors:  Jeffrey J Sutherland; Thomas M Daly; Xiong Liu; Keith Goldstein; Joseph A Johnston; Timothy P Ryan
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.